Roflumilast foam (ARQ-154)

Overview

Roflumilast foam (ARQ-154) is being investigated for the treatment of scalp and body psoriasis.

Roflumilast foam 0.3%, which has a similar composition to roflumilast cream (ARQ-151), is uniquely formulated as an emollient, water-based (~65% water) foam without fragrances, propylene glycol, isopropyl alcohol, or ethanol, and is designed with innovative, fast-breaking properties to promote delivery of active drug. It contains an exclusive emulsifier designed to maintain epidermal intercellular lipids and is adjusted to a stratum corneum pH at which the skin normally functions. 



scalp and body psoriasis

Roflumilast foam (ARQ-154) in scalp and body psoriasis.

Clinical landscape

  • Many topical formulations may be difficult to apply directly to hair-bearing areas or may make the appearance of hair unacceptable1
  • Scalp psoriasis is characterized by silvery white scales and is often the first manifestation of psoriasis on the body1
  • Treatment may require a formulation (eg, foam) suitable for hair-bearing areas

Proposed MOA

  • PDE4 activity is elevated in psoriatic skin2
  • Roflumilast is a highly potent,* anti-inflammatory, antipruritic PDE4 inhibitor3
  • Foam formulation is being investigated for the treatment of scalp and body psoriasis

*In vitro data. Clinical efficacy claims cannot be made.

MOA = mechanism of action

Clinical programs

Phase 3

ARRECTOR, a pivotal phase 3 study of roflumilast foam 0.3%, has been completed in patients with scalp and body psoriasis.

ClinicalTrials.gov identifier: NCT05028582

View Study Details

Study design summary4

||S-IGA Success and B-IGA Success were defined as scores of 0 or 1 (Clear or Almost Clear) with at least a 2-grade improvement from baseline.

**SI-NRS Success was defined as a ≥4-point improvement from baseline in SI-NRS score in patients with a baseline SI-NRS score of ≥4.

††WI-NRS Success was defined as a ≥4-point improvement from baseline in WI-NRS pruritus score in patients with a baseline WI-NRS pruritus score of ≥4.

B-IGA = Body Investigator’s Global Assessment, BSA = body surface area, CFB = change from baseline, PASI = Psoriasis Area and Severity Index, PSD = Psoriasis Symptom Diary, PSSI = Psoriasis Scalp Severity Index, QD = once daily, S-IGA = Scalp Investigator’s Global Assessment, SI-NRS = Scalp Itch Numeric Rating Scale, WI-NRS = Worst Itch Numeric Rating Scale.

Phase 2

A phase 2b study of roflumilast foam 0.3% in patients with scalp and body psoriasis has been completed.

ClinicalTrials.gov identifier: NCT04128007

View Study Details

Study design summary5

‡‡S-IGA Success and B-IGA Success were defined as scores of 0 or 1 (Clear or Almost Clear) with at least a 2-grade improvement from baseline.

B-IGA = Body Investigator’s Global Assessment, BSA = body surface area, PSSI = Psoriasis Scalp Severity Index, QD = once daily, S-IGA = Scalp Investigator’s Global Assessment, WI-NRS = Worst Itch Numeric Rating Scale.

References

1. Merola et al. Dermatol Ther. 2018;31:e12589. 2. Li et al. Front Pharmacol. 2018;9:1048. 3. Dong et al. J Pharmacol Exp Ther. 2016;358:413-422.  4. Data on File, Arcutis Biotherapeutics, Inc. 5. Kircik et al. Presented at the American Academy of Dermatology Annual Meeting; April 23-25, 2021; Virtual.

Arcutis Biotherapeutics logo

This website is intended for US healthcare professionals only. There may be information included that pertains to an investigational therapy or formulation that has not yet been approved for use in your country. The safety and efficacy of investigational therapies and/or formulations and/or uses have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. This information is as of 7/2024 to the best of the Company’s knowledge and Arcutis assumes no obligation to update this information.

© 2024 Arcutis Biotherapeutics, Inc. All rights reserved. MED-MULTI-2100006 v6.0 7/24